Table 3.

Table 3.1: Univariable models for time to BOS, time to BOS/death/re-tx, and time to death/re-tx. Post-transplant events were modelled as time-dependent risk factors.
Risk factor	Level	N	Univariable risk factors for BOS		Univariable risk factors for Death/Re-tx		Univariable risk factors for BOS/Death/Re-tx
Risk factor	Level	N	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
Donor (D) and recipient (R) CMV status		370		0.44		0.44		0.44
	D+R+ vs. D−R−		1.1 (0.51, 2.5)		1.1 (0.51, 2.5)		1.1 .5)
	D+R− vs. D−R−		1.7 (0.87, 3.2)		1.7 (0.87, 3.2)		1.7 (0.87, 3.2)
	D−R+ vs. D−R−		1.4 (0.62, 3.4)		1.4 (0.62, 3.4)		1.4 (0.62, 3.4)
Transplant type		382		0.28		0.11		0.39
	Single vs. living donor		8.9 (0.81, 98.5)		1.04 (0.22, 5.0)		1.6 (0.43, 6.1)
	Double vs. living donor		3.3 .46, 24.2)		0.42 (0.19, 0.93)		0.69 (0.34, 1.4)
	Heart/lung vs. living donor		2.6 (0.31, 20.8)		0.42 (0.15, 1.1)		0.69 (0.29, 1.6)
Age at transplant		382		0.11		0.13		0.81
	0–5.4 vs. 16.6 –20.6		0.43 (0.13, 1.4)		0.88 (0.44, 1.8)		0.70 (0.38, 1.3)
	5.511.3 vs. 16.6 –20.6		1.7 (0.74, 3.8)		0.55 (0.25, 1.2)		0.80 (0.45, 1.4)
	11.4–14.1 vs. 16.6 –20.6		1.3 (0.54, 3.0)		0.68 (0.32, 1.4)		0.81 (0.45, 1.4)
	14.2–16.5 vs. 16.6 –20.6		1.7 (0.74, 3.7)		0.32 (0.13, 0.81)		0.75 (0.42, 1.3)
Era of transplant		383		0.011		0.11		<0.001
	1985–1994 vs. 2003–2005		4.1 (1.5, 11.1)	0.005	2.0 (0.88, 4.3)	0.098	3.2 (1.6, 6.3)	<0.001
	1995–1997 vs. 2003–2005		1.6 (0.57, 4.7)	0.35	0.88 (0.37, 2.1)	0.78	1.4 (0.69, 3.0)	0.34
	1998–1999 vs. 2003–2005		1.4 (0.44, 4.4)	0.57	0.87 0.34, 2.3)	0.78	1.3 (0.58, 2.8)	0.55
	2000–2002 vs. 2003–2005		2.1 (0.77, 5.7)	0.15	0.91 0.39, 2.1)	0.83	1.5 (0.76, 3.1)	0.24

Table 3.2: Univariable models for time to BOS, time to BOS/death/re-tx, and time to death/re-tx. Post-transplant events were modelled as time-dependent risk factors.
			Univariable risk factors for BOS		Univariable risk factors for Death/Re-tx		Univariable risk factors for BOS/Death/Re-tx
Risk factor	Level	N	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value	Hazard ratio	P-value (95% CI)
Female gender		383	0.83 (0.49, 1.4)	0.47	0.84 (0.50, 1.4)	0.49	0.82 (0.56, 1.2)	0.30
Cystic fibrosis etiology		383	1.2 (0.70, 2.0)	0.55	1.03 (0.62, 1.7)	0.91	1.1 (0.76, 1.6)	0.56
Any induction treatment		351	1.08 0.63, 1.9)	0.77	0.82 (0.48, 1.4)	0.45	0.91 (0.61, 1.4)	0.66
Cyclosporine		383	2.6 (1.2, 5.6)	0.011	1.09 (0.61, 1.9)	0.78	1.6 (0.99, 2.5)	0.056
Caucasian		382	NA	0.98	1.2 (0.49, 3.1)	0.66	2.4 (0.99, 6.0)	0.052
PFI prior to event		383	1.3 (0.67, 2.6)	0.42	2.4 (1.3, 4.3)	0.005	1.7 (1.02, 2.7)	0.041
PTLD prior to event		383	1.5 (0.58, 3.7)	0.42	1.7 (0.61, 4.9)	0.31	1.4 (0.65, 3.1)	0.38
BOS prior to event		383	NA		6.2 (3.0, 12.8)	<0.001	NA
RVI prior to event		383	1.2 (0.56, 2.7)	0.60	3.0 (1.6, 5.6)	<0.001	2.1 (1.3, 3.5)	0.005
CMV syndrome/disease prior to event		383	1.3 (0.70, 2.5)	0.38	2.5 (1.3, 4.8)	0.004	1.7 (1.05, 2.8)	0.030

BOS, bronchiolitis obliterans syndrome; CMV, cytomegalovirus, PFI, pulmonary fungal infection; PTLD, post-transplant lympho-proliferative disease; RVI, respiratory viral infection; Re-tx, re-transplantation